Inovio Pharmaceuticals Stock Total Debt
| INO Stock | USD 1.96 0.14 6.67% |
Inovio Pharmaceuticals fundamentals help investors to digest information that contributes to Inovio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Inovio Stock. The fundamental analysis module provides a way to measure Inovio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inovio Pharmaceuticals stock.
As of the 19th of March 2025, Total Debt To Capitalization is likely to drop to 0.14. Inovio | Total Debt |
Inovio Pharmaceuticals Company Total Debt Analysis
Inovio Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Inovio Pharmaceuticals Total Debt | 30.21 M |
Most of Inovio Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inovio Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Inovio Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Inovio Pharmaceuticals is extremely important. It helps to project a fair market value of Inovio Stock properly, considering its historical fundamentals such as Total Debt. Since Inovio Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inovio Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inovio Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Inovio Total Debt Historical Pattern
Today, most investors in Inovio Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Inovio Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Inovio Pharmaceuticals total debt as a starting point in their analysis.
Inovio Pharmaceuticals Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Inovio Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Inovio Pharmaceuticals has a Total Debt of 30.21 M. This is 98.9% lower than that of the Biotechnology sector and 90.7% lower than that of the Health Care industry. The total debt for all United States stocks is 99.43% higher than that of the company.
Inovio Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inovio Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inovio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Inovio Pharmaceuticals by comparing valuation metrics of similar companies.Inovio Pharmaceuticals is currently under evaluation in total debt category among its peers.
Inovio Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inovio Pharmaceuticals from analyzing Inovio Pharmaceuticals' financial statements. These drivers represent accounts that assess Inovio Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inovio Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 1.0B | 372.3M | 49.7M | 44.7M | 42.5M | |
| Enterprise Value | 1.2B | 1.0B | 358.0M | (53.9B) | (62.0B) | (58.9B) |
Inovio Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inovio Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inovio Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Inovio Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Inovio Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inovio Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inovio Pharmaceuticals' value.| Shares | Ubs O'connor Llc | 2024-12-31 | 225 K | Northern Trust Corp | 2024-12-31 | 219.1 K | Ubs Group Ag | 2024-12-31 | 177 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 133.3 K | Gmt Capital Corp | 2024-12-31 | 126.1 K | Wolverine Asset Management Llc | 2024-12-31 | 97.4 K | Deutsche Bank Ag | 2024-12-31 | 89.9 K | Fmr Inc | 2024-12-31 | 81.4 K | Dimensional Fund Advisors, Inc. | 2024-12-31 | 79.1 K | Deep Track Capital, Lp | 2024-12-31 | 3.1 M | Blackrock Inc | 2024-12-31 | 1.9 M |
Inovio Fundamentals
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | (596.85) % | ||||
| Current Valuation | 3.45 M | ||||
| Shares Outstanding | 36.1 M | ||||
| Shares Owned By Insiders | 0.60 % | ||||
| Shares Owned By Institutions | 37.22 % | ||||
| Number Of Shares Shorted | 5.38 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 1.03 X | ||||
| Price To Sales | 376.24 X | ||||
| Revenue | 832.01 K | ||||
| Gross Profit | (81.77 M) | ||||
| EBITDA | (130.39 M) | ||||
| Net Income | (135.12 M) | ||||
| Cash And Equivalents | 348.13 M | ||||
| Cash Per Share | 1.40 X | ||||
| Total Debt | 30.21 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 2.82 X | ||||
| Cash Flow From Operations | (124.37 M) | ||||
| Short Ratio | 7.86 X | ||||
| Earnings Per Share | (4.43) X | ||||
| Target Price | 9.5 | ||||
| Number Of Employees | 127 | ||||
| Beta | 0.92 | ||||
| Market Capitalization | 76.53 M | ||||
| Total Asset | 170.95 M | ||||
| Retained Earnings | (1.62 B) | ||||
| Working Capital | 110.54 M | ||||
| Current Asset | 171.85 M | ||||
| Current Liabilities | 31.47 M | ||||
| Net Asset | 170.95 M |
About Inovio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inovio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inovio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inovio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock: Check out Inovio Pharmaceuticals Piotroski F Score and Inovio Pharmaceuticals Altman Z Score analysis. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share | Quarterly Revenue Growth (0.55) | Return On Assets | Return On Equity |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.